LYN and neoplasm: Dasatinib interfered with the interaction between Lyn and CD19 or PI3K p85, resulting in reduced phosphorylation of Akt/mTOR in BTZ-resistant cells and significant inhibition of tumor size in a BTZ-resistant xenograft in mouse (Figure 5).